Sign in

You're signed outSign in or to get full access.

TB

Talis Biomedical Corp (TLIS)·Q2 2023 Earnings Summary

Executive Summary

  • Q2 2023 revenue was $0.581M, flat year-over-year; operating expenses declined 39% YoY to $16.972M; net loss narrowed to $15.0M (from $27.0M) as cost controls took hold .
  • Management advanced its regulatory roadmap: COVID-19 510(k) clinical study ~⅔ enrolled with submission targeted for early 2024; plan to secure clearance for three panels (COVID instrument, FLUVID with CLIA waiver, CT/NG/TV) by end of 2025 .
  • Cash was $98.2M with no debt; average monthly burn tracking at $4–5M; trajectory supports runway into 2025, but management acknowledged future capital raise will be needed to fund commercialization .
  • Potential stock catalysts: FDA submission for COVID-19 510(k) in early 2024, CLIA waiver decision for FLUVID, CT/NG/TV clinical study initiation progress, and further non-dilutive grant inflows .

What Went Well and What Went Wrong

What Went Well

  • Cost discipline: Operating expenses fell to $16.972M (from $27.8M YoY), driving a smaller net loss and improved cash burn trajectory .
  • R&D milestones: CT/NG/TV feasibility showed performance comparable to on‑market molecular tests in <30 minutes; Candida lysis achieved in <4 minutes, supporting a differentiated vaginal infection panel .
  • Regulatory execution: “Our COVID-19 study is underway… we are well positioned to deliver 3 cleared test panels for the women’s and sexual health markets by the end of 2025.” — CEO Rob Kelley .

What Went Wrong

  • Minimal commercial revenue: Q2 revenue remained grant-led ($0.533M grant; $0.048M product), underscoring limited near-term commercialization .
  • Regulatory timelines extend de‑risking but push revenue ramp: COVID-19 510(k) submission shifted to early 2024 given FDA timing; CT/NG/TV remains a complex, longer study (low prevalence, composite comparator) .
  • Future financing need: “We know that we will have to raise capital in order to fund our future growth and commercialization down the line.” — Interim CFO Rebecca Markovich .

Financial Results

MetricQ4 2022Q1 2023Q2 2023
Total Revenue ($USD Millions)$0.257 $1.000 $0.581
Grant Revenue ($USD Millions)$0.150 N/A $0.533
Product Revenue ($USD Millions)$0.107 N/A $0.048
Total Operating Expenses ($USD Millions)$28.369 $20.000 $16.972
R&D ($USD Millions)$15.242 $14.000 $10.555
SG&A ($USD Millions)$10.795 $6.000 $6.410
Net Loss ($USD Millions)$26.929 N/A $15.000
Cash and Equivalents ($USD Millions)$130.191 $113.000 $98.200
Diluted EPS ($USD)N/A N/A N/A

Notes:

  • Q2 2023 call commentary referenced $0.5M revenue; the press release reported $0.581M total revenue (grant $0.533M; product $0.048M). We anchor to press release values .

Segment revenue breakdown (Q2 2023):

SegmentQ2 2023 ($USD Millions)
Grant Revenue$0.533
Product Revenue$0.048

KPIs:

KPIQ4 2022Q1 2023Q2 2023
Avg Monthly Cash Burn ($USD Millions)N/A $4–$5 $4–$5
Net Cash Used in Ops (YTD vs prior year)N/A 62% improvement YoY (Q1) 53% improvement YTD YoY
Cartridge Capacity (units/day)N/A 2,000 (semi-automated Chicago line) 2,000 (semi-automated Chicago line)
COVID-19 Clinical Study Enrollment ProgressN/A Initiated ~⅔ to target (50 positives/500 negatives)

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
COVID-19 510(k) submission timingSubmission windowInitiating clinical study; timelines to be finalized Expect submission in early 2024 Raised specificity (added timeline)
Panels clearedBy end of 2025Focused menu; pursue FLUVID 510(k) then CT/NG Target 3 clearances: C19 instrument, FLUVID (with CLIA waiver), CT/NG/TV Maintained objective; refined plan
CLIA waiver strategyFLUVIDNot explicitly stated as CLIA waiver in Q1 (pursue 510(k)) Apply for CLIA waiver with FLUVID to de‑risk CT/NG/TV New detail (de‑risking)
Cash runwayThrough 2025Into 2025 Into 2025 Maintained
Monthly cash burnNear term$4–$5M per month target $4–$5M per month target Maintained

Earnings Call Themes & Trends

TopicPrevious Mentions (Q4 2022)Previous Mentions (Q1 2023)Current Period (Q2 2023)Trend
Regulatory roadmapPlan to lay out 2023 milestones; refocus on women’s & sexual health Presubs filed; initiate COVID-19 510(k) clinical study; FLUVID 510(k) next COVID-19 study ~⅔ enrolled; submission early 2024; three clearances targeted by end 2025; HSV presub underway Accelerating clarity
ManufacturingScale-up largely completed; cost reductions Three-tier capacity (manual, semi-auto 2,000/day, fully auto 40,000/day); raw materials in place Semi-auto Chicago line operational; new instrument maker; US raw card partner; license for component manufacturing Optimization/streamlining
Cash managementCash $130.2M; reduced burn; runway into 2025 Cash $113M; burn down to $4–$5M/month; 62% YoY improvement in cash used Cash $98.2M; 53% YTD improvement; continued burn discipline; future raise needed Improving burn; acknowledge funding need
Market demand & product focusStrong interest in point-of-care women’s health testing 84% adoption interest; ~40% would run respiratory at point-of-care Emphasis on CT/NG/TV as adoption driver; FLUVID to seed platform use Consistent positive demand
R&D execution—Targeted menu; COVID/FLU; CT/NG; HSV; vaginal panel plan CT/NG/TV feasibility and Candida lysis data presented at IDSOG; <30 min turnaround positioning De-risking assays

Management Commentary

  • “Our team’s focused execution is delivering progress… We believe we are well positioned to deliver 3 cleared test panels for the women’s and sexual health markets by the end of 2025.” — CEO Rob Kelley .
  • “Unrestricted cash and cash equivalents as of June 30, 2023, were $98 million… our objective is to ensure that our current cash reserves are sufficient to fund operations into 2025.” — Interim CFO Rebecca Markovich .
  • “We are going to be applying… for the instrument for CLIA waiver with the FLUVID product… de‑risks our CT/NG/TV submission.” — CEO Rob Kelley .
  • “We know that we will have to raise capital in order to fund our future growth and commercialization down the line.” — Interim CFO Rebecca Markovich .
  • “CT/NG is… an adoption driver, a volume driver… when we think about full‑scale commercialization, we’re thinking about linking that up with the clearance of CT/NG/TV.” — CEO Rob Kelley .

Q&A Highlights

  • COVID-19 clinical study: Designed for 50 positives/500 negatives across four sites; ~⅔ enrolled; submission targeted early 2024 given FDA year‑end dynamics .
  • Panel clearance strategy: Target three clearances by end 2025 (COVID instrument, FLUVID + CLIA waiver, CT/NG/TV); HSV presub underway with potential pull‑in to 2025 .
  • Commercialization cadence: Limited pre‑CT/NG commercialization; CT/NG/TV expected to drive adoption and volume once cleared .
  • Cash burn and financing: Burn tracking $4–$5M/month; cash $98M with no debt; management expects to raise capital to fund commercialization .

Estimates Context

  • Wall Street consensus (S&P Global) for TLIS EPS and revenue around Q2 2023 was unavailable due to missing CIQ mapping; therefore comparison to estimates cannot be provided at this time [tool error from GetEstimates].
  • Given the lack of published consensus, investors should anchor on company-reported figures and monitor any subsequent analyst coverage updates.

Key Takeaways for Investors

  • Regulatory catalysts in 6–12 months: Early 2024 COVID-19 510(k) submission, followed by FLUVID CLIA waiver and CT/NG/TV progress — timeline clarity reduces program risk .
  • R&D de‑risking: Strong CT/NG/TV feasibility and Candida lysis results support differentiation for <30‑minute point‑of‑care testing in women’s health .
  • Cost discipline is working: OpEx down materially YoY; YTD operating cash use improved 53% YoY; burn stabilized at $4–$5M/month .
  • Balance sheet provides runway into 2025, but expect an eventual capital raise to fund commercialization — a key overhang and potential valuation inflection depending on terms .
  • Near-term commercialization remains limited (grant-driven revenue); adoption ramp likely contingent on CT/NG/TV clearance, which management views as the main demand driver .
  • Manufacturing and supply chain changes (new instrument partner, US raw card supplier, license for components) should support quality, speed, and scale readiness ahead of launches .
  • Trading implications: Watch for FDA submission and CLIA waiver updates; any acceleration of CT/NG/TV clinical timeline or non‑dilutive funding could be positive; equity financing risk is a moderating factor .

References:

  • Q2 2023 earnings call transcript ; duplicate transcript .
  • Q2 2023 press release (GlobeNewswire) ; SEC 8-K reference to press release .
  • Q1 2023 earnings call transcript .
  • Q4 2022 8-K press release and financials .